New Republic Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-250
Closed -$19.1K – 251
2023
Q1
$19.1K Hold
250
– – 0.01% 201
2022
Q4
$20.8K Buy
+250
New +$20.2K 0.02% 161

Other funds holding XBI

New Republic Capital's XBI Position: Q2 2023 in Review

New Republic Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 250 shares — an estimated $19.1K sold.

New Republic Capital first reported a position in XBI in Q4 2022 and held it in 2 quarters. The position peaked at $20.8K in Q4 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

  • New Republic Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
  • New Republic Capital sold 250 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $19.1K.
  • New Republic Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 2 quarters.
  • New Republic Capital's State Street SPDR S&P Biotech ETF position peaked at $20.8K in Q4 2022.
  • 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on New Republic Capital's 13F filing for Q2 2023, filed 14 Aug 2023.